Hyris Ltd established in London
Seed round of €1 million, contributions of €1.5 million.
Opening of R&D Centre in Milan, Italy
First NanoHybrid patent, Trieste laboratory.
The HYRIS bCUBE™ 1.0 has successfully completed its first run.
The first customer orders are placed, and third-party integration activities commence.
Demonstrations to key customers and technical co-development. Initial commercial revenues have been recorded.
Hyris receives the European Commission's "Seal of Excellence" award.
Official launch. Start of development of Sagitta and NanoHybrid. Patent on biosensors.
Hyris announces its partnership and entry into the botanical applications sector.
HYRIS bCUBE™ 2.0 is available for purchase.
First prototype. €4 million raised from 1,150 shareholders. Three new patents filed.
ISO 13485 certification obtained. Virological collaboration and two patents on biomarkers.
Hyris launches its line of products for identifying probiotic strains.
Clinical validation of LadyMed. Testing of the distribution channel.
Hyris launches its environmental test for the identification of SARS-CoV-2.
Hyris receives A-Series funding.
Entry into the healthcare sector, with CE-IVD mark and Health Canada approval for SARS-CoV-2 human specimen testing.
Partnership with Menarini for Coronamelt and Coronamelt Var (PCR Covid).
Hyris presents its new Brand Identity, supporting its rapid global growth.
HYRIS bCUBE 3™ is available for purchase.
Hyris obtains ISO9001 and ISO13485 certifications.
Menarini begins production. Coronamelt Var coming in September.
Hyris obtains IS27001 certification.
First marketplace applications in product catalog.
Reverse takeover with Hyris. Integrated group for molecular diagnostics.
2024
Integration
Integration between Hyris and Ulisse Biomed completed. The Group is ready to embrace the new industrial project.
New investors
Algebris becomes a strategic shareholder in Ulisse Biomed with a capital increase of €1.3 million.
2025
Second phase of the malaria surveillance project
The Gates Foundation confirms funding for the second phase of the malaria surveillance project, in collaboration with Johns Hopkins University and CRID.
2025
Entry into the NGS market announced
Received the first order for an NGS screening kit, officially marking the entry into the genomic sequencing market.
2025
Helyx Industries is founded
Helyx Industries is an industrial group active in the field of genetics. It has proprietary technologies and processes for complete and integrated solutions in molecular biology, from PCR to NGS. Through its divisions, it offers its solutions directly to diagnostic laboratories and hospitals or provides its services to diagnostic and industrial partners.
Products and development services integrated into a revolutionary platform.
Medical products and services for molecular biology in hospitals and laboratories.
Products and services for next-generation sequencing.
